StockNews.AI
MIRA
StockNews.AI
125 days

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

1. MIRA's Ketamir-2 shows strong efficacy in diabetic neuropathy animal model. 2. Subjects demonstrated complete symptom reversal, potentially enhancing MIRA's product pipeline.

2m saved
Insight
Article

FAQ

Why Bullish?

The strong efficacy data for Ketamir-2 may attract investor interest, similar to past biotech advancements that boosted stock prices.

How important is it?

The promising results of Ketamir-2 are crucial for MIRA's growth and future funding rounds.

Why Short Term?

Immediate investor reaction expected to favorable data, with longer-term effects contingent on clinical trial success.

Related Companies

KMPHPFEJNJ
Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic and neuropsychiatric disorders, today announced compelling data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy. In the study, Type 2 diabetes was induced in rats using a high-fat diet combined with a low dose of Streptozotocin (STZ).

Related News